WO2001044478A2 - $g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes - Google Patents

$g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes Download PDF

Info

Publication number
WO2001044478A2
WO2001044478A2 PCT/US2000/033945 US0033945W WO0144478A2 WO 2001044478 A2 WO2001044478 A2 WO 2001044478A2 US 0033945 W US0033945 W US 0033945W WO 0144478 A2 WO0144478 A2 WO 0144478A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
galactosyl transferase
polynucleotide
amino acid
host cell
Prior art date
Application number
PCT/US2000/033945
Other languages
English (en)
Other versions
WO2001044478A3 (fr
WO2001044478A9 (fr
Inventor
William M. Canfield
Richard D. Cummings
Tongzhong Ju
Original Assignee
The Board Of Regents Of The University Of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,035 external-priority patent/US6492152B1/en
Application filed by The Board Of Regents Of The University Of Oklahoma filed Critical The Board Of Regents Of The University Of Oklahoma
Priority to MXPA02005953A priority Critical patent/MXPA02005953A/es
Priority to AU27273/01A priority patent/AU2727301A/en
Priority to EP00990216A priority patent/EP1240334A2/fr
Priority to CA002396654A priority patent/CA2396654A1/fr
Priority to JP2001545555A priority patent/JP2003527103A/ja
Publication of WO2001044478A2 publication Critical patent/WO2001044478A2/fr
Publication of WO2001044478A3 publication Critical patent/WO2001044478A3/fr
Publication of WO2001044478A9 publication Critical patent/WO2001044478A9/fr
Priority to HK03100430.5A priority patent/HK1048140A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)

Definitions

  • the present invention is related to core 1 ⁇ 3-galactosyl transferases, polynucleotides which encode said galactosyl transferases and methods of use thereof.
  • N-acetylgalactosamine linked to a threonine or serine on a protein, peptide or polypeptide is a critical intermediate in the biosynthesis of most extended flunked glycans (Glycoproteins and Human Disease (Brockhausen, I., and Kuhns, W., eds), (1997), pp. 13-31 , R.G. Austin).
  • the core 1 structure is found on a number of mucins and adhesion molecules.
  • Core 1 ⁇ 3- galactosyl transferase is the only enzyme which is capable of synthesizing the core 1 0-linked glycan structure Gal ⁇ 3-GalNAc-Ser/Thr.
  • Figure 1 is a table summarizing the purification of core 1 ⁇ 3-galactosyl transferase from 500 grams of rat liver.
  • Figure 2 is a SDS-PAGE gel characterizing the purification of core 1 ⁇ 3- galactosyl transferase from rat liver.
  • Figure 3 show the cDNA (SEQ ID NO:2) and protein sequence (SEQ ID NO:l) of human core 1 ⁇ 3-galactosyl transferase.
  • Figure 4 is an alignment comparison of human (SEQ ID NO:l), rat (SEQ ID NO:3), mouse (SEQ ID NO:5), two D. melanogaster (SEQ ID NO:9 and SEQ ID NO: 17) and C. elegans (SEQ ID NO:7) core 1 ⁇ 3-galactosyl transferase protein sequences.
  • core 1 ⁇ 3-galactosyl transferase and polynucleotides which encode said galactosyl transferase, as well as methods for using same is provided.
  • core 1 ⁇ 3-galactosyl transferase purified from rat liver is provided, as well as the cloned Homo sapiens, Rattus norvegicus, Mus musculus, Drosophila melanogaster, and Caenorhabdltis elegans cDNAs that encode this enzyme, designated herein as ⁇ 3-GalT.
  • the invention further comprises a soluble form of the enzyme.
  • the invention comprises homologous versions of ⁇ 3-GalT proteins encoded by homologous cDNAs, homologous cDNAs, vectors and host cells which express the cDNAs, and methods of using the ⁇ 3-GalT proteins and cDNAs.
  • the present invention contemplates cloning vectors which comprise the nucleic acid of the invention; and prokaryotic or eukaryotic expression vectors which comprise the nucleic acid molecule of the invention operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or eukaryotic cell transfected or transformed with an appropriate expression vector.
  • An object of the present invention is to provide a nucleic acid, in particular a DNA, that encodes a core 1 ⁇ 3-galactosyl transferase or a fragment thereof, or homologous derivatives or analogs thereof.
  • a further object of the present invention while achieving the before- stated object, is to provide a cloning vector and an expression vector for such a nucleic acid molecule.
  • Yet another object of the present invention while achieving the before- stated objects, is to provide a recombinant cell line that contains such an expression vector.
  • Yet a further object of the present invention is to produce core 1 ⁇ 3-galactosyl transferase and fragments thereof.
  • a still further object of the present invention while achieving the before- stated objects, is to provide methods for using core 1 ⁇ 3-galactosyl transferase and fragments thereof.
  • the core 1 O-linked glycan structure consisting of galactose in ⁇ l,3 linkage to N-acetylgalactosamine linked to a threonine or serine on a protein, peptide or polypeptide, is a critical intermediate in the biosynthesis of most extended O-linked glycans.
  • the core 1 structure is found on a number of mucins and adhesion molecules.
  • Core 1 ⁇ 3-galactosyl transferase which is capable of synthesizing the core 1 O-linked glycan structure Gal ⁇ 3-GalNAc- Thr/Ser, has been purified herein from rat liver.
  • N-terminal and internal protein sequence of the purified enzyme was obtained and used to identify human EST clones, and a full length cDNA for the human core 1 ⁇ 3-galactosyl transferase was isolated using standard molecular biology techniques.
  • the rat core 1 ⁇ 3- galactosyl transferase cDNA has also been identified.
  • the mouse, C. elegans, and two Drosophila melanogaster core 1 ⁇ 3-galactosyl transferase genes are also described herein. An alignment of the human, rat, mouse, C. elegans, and two D.
  • melanogaster core 1 ⁇ 3-galactosyl transferases is also provided, demonstrating that these are highly homologous proteins; in particular, the C. elegans protein is 41% identical to the human protein, with 7 of 9 cysteines being conserved. Also provided herein is a soluble, epitope-tagged version of the human core 1 ⁇ 3-galactosyl transferase which has been expressed and recovered from culture media.
  • the polynucleotides of the present invention may be in the form of RNA or in the form of DNA, wherein the term "DNA” includes cDNA, genomic DNA and synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single-stranded, may be the coding strand or non-coding (anti-sense) strand.
  • the coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown herein or may be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes the same, mature polypeptide as the DNA coding sequences shown herein.
  • the polynucleotides which encode the mature polypeptides may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns, or non-coding sequence 5' and/or 3" of the coding sequence for the mature polypeptide.
  • polynucleotide encoding a polypeptide'' encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
  • the present invention further relates to variants of the hereinabove described polynucleotides which encode fragments, analogs and derivatives of the polypeptide having the amino acid sequences of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9 and SEQ ID NO:17.
  • the variants of the polynucleotide may be naturally occurring allelic variants of the polynucleotides or nonnaturally occurring variants of the polynucleotides.
  • the present invention includes polynucleotides encoding the same mature polypeptides as shown in SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9 and SEQ ID NO: 17, as well as variants of such polynucleotides which encode active fragments, derivatives or analogs of said polypeptides.
  • Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
  • the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequences of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 and SEQ ID NO: 18.
  • SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8 which encode the protein sequences of SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7, respectively, are provided as SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, respectively (SEQ ID NO: 10 and SEQ ID NO: 18 contain only the open reading frames of the core 1 ⁇ 3-GalT genes and no non-coding sequences).
  • an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides which does not substantially adversely alter the function of the encoded polypeptide.
  • the present invention further relates to a ⁇ 3-GalT polypeptide which has the amino acid sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9 and SEQ ID NO: 17, as well as fragments, analogs and derivatives of such polypeptide.
  • fragment when referring to the polypeptide of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9 and SEQ ID NO: 17, refer to a ⁇ 3-GalT which retains essentially the same or increased biological functions or activities as the native ⁇ 3-GalT.
  • an analog includes a proprotein which can be activated by cleavage of a proprotein portion to produce an active mature polypeptide.
  • Fragments of core 1 ⁇ 3-GalT include soluble, active proteins which have the N-terminal transmembrane region removed.
  • polypeptide of the present invention may be a natural polypeptide or a synthetic polypeptide, or preferably a recombinant polypeptide.
  • the fragment, derivative or analog of the polypeptide of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9 and SEQ ID NO: 17 may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence.
  • polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified substantially to homogeneity.
  • isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring) in a form sufficient to be useful in performing its inherent enzymatic function.
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotides could be part of a vector, and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention, and the production of polypeptides of the invention by recombinant techniques.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
  • the vector may be, for example, in the form of a plasmid, a viral particle, or a phage or other vectors known in the art.
  • the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the ⁇ 3-GalT genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinary skilled artisan.
  • the ⁇ 3-GalT-encoding polynucleotides of the present invention may be employed for producing Gal ⁇ 3-GalNAc by recombinant techniques or synthetic in vitro techniques.
  • the ⁇ 3-GalT polynucleotides may be included along with a gene encoding a protein requiring O-linked glycosylation in any one of a variety of expression vectors for expressing the ⁇ 3-GalT and the protein requiring O-linked glycosylation.
  • Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • the protein requiring O-linked glycosylation is P-selectin glycoprotein ligand-1 or a portion thereof or a synthetic peptide which has P-selectin binding activity.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures.
  • the DNA sequence may be inserted into an appropriate restriction endonuclease sites(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of a person of ordinary skill in the art.
  • the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
  • promoter for example, LTR or SV40 promoter, the E. coli lac or trp, the phage lambda P L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein as described elsewhere herein.
  • appropriate hosts there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhim ⁇ rium; fungal cells, such as yeast; insect cells such as Drosophila and Sf9; animal cells such as CHO, COS, 293T or Bowes melanoma; plant cells, etc.
  • bacterial cells such as E. coli, Streptomyces, Salmonella typhim ⁇ rium
  • fungal cells such as yeast
  • insect cells such as Drosophila and Sf9
  • animal cells such as CHO, COS, 293T or Bowes melanoma
  • plant cells etc.
  • the selection of an appropriate host is deemed to be within the scope of a person of ordinary skill in the art given the teachings herein.
  • the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
  • the constructs comprise a vector, such as a plasmid or viral vector, Into which a sequence of the invention has been inserted, in a forward or reverse orientation.
  • the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
  • a promoter operably linked to the sequence.
  • Bacterial PQE70, pQE60, pQE-9 (Qiagen), pbs, pDIO, phagescript, psiX174, pBluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223- 3, pKK233-3, pDR540, pRIT5 (Pharmacia).
  • Eukaryotic pWLNEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
  • Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
  • CAT chloramphenicol transferase
  • Two appropriate vectors are PKK232-8 and PCM7.
  • Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda P R , P L and trp.
  • Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • the present invention relates to host cells containing the above-described constructs.
  • the host cells may be obtained using techniques known in the art. Suitable host cells include prokaryotic or lower or higher eukaryotic organisms or cell lines, for example bacterial, mammalian, yeast, or other fungi, viral, plant or insect cells. Methods for transforming or transfecting cells to express foreign DNA are well known in the art (See for example, Itakura et al., U.S. Pat. No. 4,704,362; Hinnen et al., PNAS USA 75: 1929-1933, 1978; Murray etal., U.S. Pat. No.4,801,542; Upshall et al., U.S. Pat. No.
  • constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
  • the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
  • Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby inco ⁇ orated herein by reference. Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer, a cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cere visiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
  • Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosoglycerate kinase (PGK), ⁇ -factor, acid phosphatase, or heat shock proteins, among others.
  • PGK 3-phosoglycerate kinase
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracelluar medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal or C-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
  • Useful expression vectors for bacterial use are constructed by inserting one or more structural DNA sequences encoding one or more desired proteins together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
  • the vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.
  • Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.
  • useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322, (ATCC 37017). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate methods (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
  • Cells are typically harvested by centrifugation, disrupted by physical or chemical methods, and the resulting crude extract retained for further purification.
  • Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to a person of ordinary skill in the art.
  • Various mammalian cell culture systems can also be employed to express recombinant protein.
  • mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman (Cell, 23:175 (1981)), and other cell lines capable of transcribing compatible vectors, for example, the C127, 293T, 3T3, CHO, HeLa and BHK cell lines.
  • Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
  • the ⁇ 3-GalT polypeptides or portions thereof can be recovered and purified from recombinant cell cultures by methods including but not limited to ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyl apatite chromatography, and lectin chromatography, alone or in combination. Protein refolding steps can be used as necessary in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non- glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.
  • a recombinant ⁇ 3-GalT of the invention, or functional fragment, derivative or analog thereof, may be expressed chromosomally, after integration of the ⁇ 3-GalT coding sequence by recombination.
  • any of a number of amplification systems may be used to achieve high levels of stable gene expression (See Sambrook et al., 1989, supra).
  • the cell into which the recombinant vector comprising the nucleic acid encoding the ⁇ 3-GalT is cultured in an appropriate cell culture medium under conditions that provide for expression of the ⁇ 3-GalT by the cell. If full length ⁇ 3-GalT is expressed, the expressed protein will comprise an integral transmembrane portion. If a ⁇ 3-GalT lacking a transmembrane domain is expressed, the expressed soluble ⁇ 3-GalT can then be recovered from the culture according to methods well known to persons of ordinary skill in the art. Such methods are described in detail, infra.
  • Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombination.
  • the polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto.
  • These antibodies can be, for example, polyclonal or monoclonal antibodies.
  • the present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab (F(ab')2 fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.
  • Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by other appropriate forms of administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495- 497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • the polyclonal or monoclonal antibodies may be labeled with a detectable marker including various enzymes, fluorescent materials, luminescent materials and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase
  • suitable fluorescent materials include umbeliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin
  • examples of luminescent materials include luminol and aequorin
  • suitable radioactive material include S 35 , Cu 64 , Ga 67 , Zr 89 , Ru 97 , Tc 99m , Rh 105 , Pd 109 , In 111 , 1 123 , 1 125 , 1 131 , Re 186 , Au 198 , Au 199 , Pb 203
  • nucleotide coding sequences which encode substantially the same amino acid sequence as a ⁇ 3- GalT gene described herein may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of ⁇ 3-GalT genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change.
  • the ⁇ 3-GalT derivatives of the invention include, but are not limited to those containing, as a primary amino acid sequence, all or part of the amino acid sequence of the ⁇ 3-GalT protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence, resulting in a conservative amino acid substitution.
  • one or more amino acid residues within the sequence can be substituted for another amino acid of a similar polarity, which acts as a functional equivalent.
  • Substitutions for an amino acid within the sequence may be selected from, but are not limited to, other members of the class to which the amino acid belongs.
  • the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar (neutral) amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamlne.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • the cloned ⁇ 3-GalT gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, supra). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro. In the production of the gene encoding a derivative or analog of ⁇ 3-GalT, care should be taken to ensure that the modified gene remains within the same translational reading frame as the ⁇ 3-GalT coding sequence, uninterrupted by translation stop signals, in the gene region where the desired activity is encoded.
  • ⁇ 3-GalT may include various structural forms of the primary protein which retain biological activity.
  • ⁇ 3-GalT polypeptide may be in the form of acidic or basic salts or in neutral form.
  • individual amino acid residues may be modified by oxidation or reduction.
  • various substitutions, deletions or additions may be made to the amino acid or nucleic acid sequences, the net effect being that biological activity of ⁇ 3-GalT is retained. Due to code degeneracy, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid. Mutations in nucleotide sequences constructed for expression of derivatives of ⁇ 3-GalT polypeptide must preserve the reading frame phase of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins which could adversely affect translation of the mRNA.
  • Mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.
  • oligonucleotide-directed site specific mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required.
  • Deletions or truncations of ⁇ 3-GalTs may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated.
  • a nucleic acid sequence encoding a ⁇ 3-GalT can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
  • such mutations enhance the functional activity of the mutated ⁇ 3-GalT gene product.
  • mutagenesis Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson, C, et al., 1978, J. Biol. Chem. 253:6551; Zoller and Smith, 1984, DNA 3:479-488; Oliphant et al., 1986, Gene 44: 177; Hutchinson et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:710), use of TAB® linkers (Pharmacia), etc.
  • PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCRto Engineer DNA", in PCR Technology: Principles and Applications for DNA amplification, H. Eriich, ed., Stockton Press, Chapter 6, pp. 61-70).
  • nucleic acid molecule of the invention also permits the identification and isolation, or synthesis of nucleotide sequences which may be used as primers to amplify a nucleic acid molecule of the invention, for example in the polymerase chain reaction (PCR) which is discussed in more detail below.
  • the primers may be used to amplify the genomic DNA of other species which possess ⁇ 3-GalT activity.
  • the PCR amplified sequences can be examined to determine the relationship between the various ⁇ 3-GalT genes.
  • the length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length.
  • Primers which may be used in the invention are oligonucleotides of the nucleic acid molecule of the invention which occur naturally, as in purified products of restriction endonuclease digest, or are produced synthetically using techniques known in the art, such as phosphotriester and phosphodiesters methods (See Good et al., Nucl. Acid Res 4:2157, 1977) or automated techniques (See for example, Conolly, B.A. Nucleic Acids Res. 15:15(8 ⁇ 7): 3131, 1987).
  • the primers are capable of acting as a point of initiation of synthesis when placed under conditions which permit the synthesis of a primer extension product which is complementary to the DNA sequence of the invention i.e., in the presence of nucleotide substrates, an agent for polymerization, such as DNA polymerase, and at suitable temperature and pH.
  • the primers are sequences that do not form secondary structures by base pairing with other copies of the primer or sequences that form a hair pin configuration.
  • the primer may be single or double-stranded. When the primer is double-stranded it may be treated to separate its strands before using to prepare amplification products.
  • the primer preferably contains between about 7 and 50 nucleotides.
  • the primers may be labeled with detectable markers which allow for detection of the amplified products.
  • detectable markers are radioactive markers such as P 32 , S 35 , I 125 , and H 3 , luminescent markers such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluorocein-5-isothiocyanate, and 4-fluor-7-nitrobenz- 2-axa-l,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, acetylcholinesterase, or biotin.
  • the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide sequence thereof which is to be amplified. Restriction site linkers may also be incorporated into the primers, allowing for digestion of the amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.
  • a method of determining the presence of a nucleic acid molecule having a sequence encoding a ⁇ 3-GalT, or a predetermined oligonucleotide fragment thereof in a sample comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or the predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of amplified sequences, and assaying for amplified sequences.
  • the polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al., Academic Pres,
  • LCR Ligase Chain Reaction
  • NASBA is a continuous amplification method using two primers, one incorporating a promoter sequence recognized by an RNA polymerase and the second derived from the complementary sequence of the target sequence to the first primer (U.S. Pat. No. 5,130,238 to Malek).
  • the present invention also provides novel fusion proteins in which any Of the enzymes of the present invention are fused to a polypeptide such as protein A, streptavidin, fragments of c-myc, maltose binding protein, IgG, IgM, amino acid tag, etc.
  • a polypeptide such as protein A, streptavidin, fragments of c-myc, maltose binding protein, IgG, IgM, amino acid tag, etc.
  • the polypeptide fused to the enzyme of the present invention is chosen to facilitate the release of the fusion protein from a prokaryotic cell or a eukaryotic cell, into the culture medium, and to enable its (affinity) purification and possibly immobilization on a solid phase matrix.
  • the present invention provides novel DNA sequences which encode a fusion protein according to the present invention.
  • the present invention also provides novel immunoassays for the detection and/or quantitation of the present enzymes in a sample.
  • the present immunoassays utilize one or more of the present monoclonal or polyclonal antibodies which specifically bind to the present enzymes.
  • the present immunoassays utilize a monoclonal antibody.
  • the present immunoassay may be a competitive assay, a sandwich assay, or a displacement assay, such as those described in Harlow, E. et al., Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988) and may rely on the signal generated by a radiolabel, a chromophore, or an enzyme, such as horseradish peroxidase.
  • the core 1 ⁇ 3-galactosyl transferase enzymes of the present invention can be used for in vitro synthesis of glycosulfopeptides to block selectin: ligand interactions.
  • Other potential uses for the core 1 3-galactosyl transferase enzymes of the present invention which can be envisioned include diagnostic tests for the rare Tn-syndrome or IgA nepropathy, as well as for therapy of these disorders.
  • the invention will be more fully understood by reference to the following examples. However, the examples are merely intended to illustrate embodiments of the invention and are not to be construed to limit the scope of the invention.
  • Core 1 ⁇ 3-Galactosyl Transferase Activity was assayed as previously described (Brockhausen, I. (1992) Biochem and Cell Biol 70:99) with the following modifications.
  • the assay contained the following: 100 mM MES pH 6.8, 0.2% Triton X-100, 20 mM MnCI 2 , 1 mM phenyl- ⁇ -GalNAc, 4 mM [ 3 H]-UDP-Gal (100,000-150,000 dpm/nmol), 2 mM ATP and 5-25 ⁇ l sample containing core 1 ⁇ 3-GalT in a total volume of 50 ⁇ l.
  • the enzyme has been purified from rat liver using an affinity chromatographic step consisting of immobilized bovine submaxillary mucin that has been neuraminidase treated and coupled to UltraLinkTM.
  • the enzyme binds tightly to this support and is eluted with high salt. Due to the tight binding, core 1 ⁇ 3-GalT elutes late in the elution pattern after most nonspecific binding proteins have already eluted. Final purification was achieved by gel filtration chromatography on Superose 12. Overall, the enzyme was purified 71, 000-fold in 8% yield, as shown in Figures 2 and 3.
  • Step 1 Homogenization, Subcellular Fractionation, Isolation of Membranes and Solubilization.
  • 500 grams fresh rat liver was washed with cold 150 mM NaCl in 25 mM Tris-HCI pH 7.4 and homogenized with 2,000 ml of buffer containing 25 mM Tris-HCI pH 7.5, 0.25 M Sucrose, 1 mM PMSF, 2 ⁇ g/ml Leupeptin, 1 mM Benzamidine, and 0.7 ⁇ g/ml Pepstatin A in a Waring commercial blender.
  • the homogenate was centrifuged at 20,000xg for 20 minutes, and the supernatant was then decanted and centrifuged at 100,000 g for 60 minutes.
  • the pellets were suspended in 5 volumes of buffer containing 50 mM Tris-HCI pH 9.0, 0.25 M Sucrose, 1 mM PMSF, 1 mM Benzamidine, 0.7 ⁇ g/ml Pepstatin A, and 2 ⁇ g/ml Leupeptin.
  • the suspension was sonicated four times for 10 seconds each in an ice-bath, extracted in ice for 1 hour, and then centrifuged at 100,000 gr for 60 minutes. The supernatant was collected and the pH adjusted using 1 mM MES. The approximate volume of the supernatant containing solubilized membrane proteins was 1,000 ml.
  • Step 2 SP-Sepharose FF Chromatography.
  • solubilized membrane proteins were applied onto a 6 x 20 cm SP-Sepharose FF column (Pharmacia BioTech) which was equilibrated with equilibration buffer, which contains 25 mM MES pH 6.5, 0.1% Triton X-100, 5 mM MnCI 2 , 1 mM PMSF, 1 mM Benzamidine, 0.7 ⁇ g/ml Pepstatin A, and 2 ⁇ g/ml Leupeptin.
  • the column was washed with the same buffer, and then the core 1 ⁇ 3-GalT was step-eluted using 1 M NaCl in equilibration buffer.
  • Step 3 Asialo-BSM UltraLinkTM Chromatography.
  • the SP-Sepharose elute was dialyzed and concentrated into equilibration buffer in an Amicon concentrator using a YM30 membrane.
  • the sample was loaded onto a 1 x 5 cm Asialo-BSM UltralinkTM column equilibrated with a second equilibration buffer, which contains 25 mM MES pH 6.8, 0.01% Triton X-100, 10 mM MnCI 2 , 150 mM NaCl, 1 mM PMSF, 1 mM Benzaminidine, 2 ⁇ g/ml Leupeptin, and 0.7 ⁇ g/ml Pepstatin A.
  • core 1 ⁇ 3-GalT was eluted with 1 M NaCl in the second equilibration buffer without MnCI 2 . Fractions were collected, and activity of core 1 ⁇ 3-GalT was assayed as described above. The fractions which contained core 1 ⁇ 3-GalT were then pooled.
  • Step 4 Superose 12 Chromatography.
  • the pooled samples containing core 1 ⁇ 3-GalTfrom Asialo-BSM UltraLinkTM chromatography were concentrated to a final volume of 200 ⁇ l using Centriprep 30 and Centricon 30 concentrators, loaded on a 1.5 x 35 cm Superose 12 column (Pharmacia BioTech) equilibrated with a third equilibration buffer, which contains 25 mM Tris-HCI pH 7.2, 0.005% Triton X-100, and 150 mM NaCl.
  • Core 1 ⁇ 3-GalT was eluted with the same buffer, and fractions were pooled and assayed as described above.
  • amino-terminal and internal protein sequence was obtained by standard molecular biology techniques. BlastP searching of the NCBI EST database using the rat core 1 ⁇ 3-GalT N-terminal peptide sequence identified a rat EST, AI059600.
  • Amplification was carried out at 94°C for 1 minute followed by 35 cycles of 94°C for 30 seconds and 68°C for 2 minutes, then the reaction was held at 68°C for 10 minutes.
  • the 450 bp product was purified using a QIA-quick column, ligated into PCR2.1, and sequenced.
  • the 1794 bp cDNA encoding human core 1 ⁇ 3-GalT is shown in SEQ ID NO:2.
  • the cDNA (SEQ ID NO:2) and protein sequence (SEQ ID NO:l) of human core 1 ⁇ 3-GalT is shown in Figure 4.
  • An open reading frame (SEQ ID NO: 12) of SEQ ID NO:2 encodes a 363 amino acid type 2 transmembrane protein.
  • the predicted 28 amino acid transmembrane domain (SEQ ID NO: 16) is underlined in Figure 3.
  • An expression vector encoding the wild-type human core 1 ⁇ 3-Gal-T was constructed by ligating a 1.5 kb Xbal/Xhol fragment of EST T10488 with a BamHI/XhoI digested pcDNA3.1(+) vector (Invitrogen), a 155 bp Apol/Xbal fragment from the cloned 5'-RACE product, and annealed oligonucleotides 5'- GATCCACCATGGCC_TCTAAATCCTGGCTG-3 , (SEQ ID NO: 19) and 5'- AATTCAGCCAGGATTTAGAGGCCATGGTG-3' (SEQ ID NO:20).
  • Human embryonic kidney 293-T cells in 100 mm dishes were transiently transfected with wild-type expression vector using FuGENETM6 according to the manufacturer's protocol and cultured in low-glucose Dulbecco's modified Eagle's media containing 10% Fetal Calf Serum.
  • Cells were harvested at 24, 48 and 72 h, washed twice with cold TBS (25 mM Tris-HCI pH 7.4, 150 mM NaCl) and sonicated on ice (10 seconds, 3 times, Branson Cell Disruptor model 185, setting 5) in 300-500 ⁇ l of TBS containing 1 mM PMSF, 1 mM benzaminidi ⁇ e- HCI, 2 ⁇ g/ml leupeptin.
  • An expression vector encoding soluble epitope- tagged core 1 ⁇ 3-GalT was constructed by ligating a 1584 bp Bsml/Xhol fragment from EST T10488 with BamHI/XhoI digested pcDNA3.1(+)-TH (a modified form of the pcDNA3.1(+) vector constructed for expression of fusion proteins containing an NH 2 -terminal epitope for HPC4, a Ca 2+ -dependent monoclonal antibody to Protein C (Rezaie et al. (1992) J. Biol. Chem.
  • Additional amino acids 20-31 correspond to the HPC4 epitope tag.
  • the soluble form of core 1 ⁇ 3-GalT which is secreted from the cell will have the signal peptide sequence removed but will still contain the HPC4 epitope tag.
  • HPC4-Affi-Gel 10 (15 ⁇ l) equilibrated with equilibration buffer (50 mM Tris-HCI pH 7.2, 100 mM NaCl and 1 mM CaCI 2 ) was incubated with 500 ⁇ l media at 4°C on a rotator for 2 h, spun for 5 minutes in a microcentrifuge at 14,000 g, and both beads and supernatant were collected and saved. The beads were washed three times with 500 ⁇ l of 50 mM Tris-HCI pH 7.4, 1 mM NaCl, 1 mM CaCI 2 and once with equilibration buffer. The beads, media and supernatant were then assayed in the absence of Triton X-100 for core 1 ⁇ 3- GalT activity as described herein before.
  • equilibration buffer 50 mM Tris-HCI pH 7.2, 100 mM NaCl and 1 mM CaCI 2
  • musculus core 1 ⁇ 3-GalT has 89% identity and 94% similarity to the human enzyme (SEQ ID NO: l).
  • the 1172 bp C. elegans ⁇ 3-GalT gene is shown in SEQ ID NO:8, and an open reading frame corresponding to bases 1-1170 of SEQ ID NO:8, shown in SEQ ID NO: 15, encodes the protein sequence of C. elegans core 1 ⁇ 3-GalT (SEQ ID NO:7).
  • the C. elegans core 1 ⁇ 3-GalT has 41% identity and 58% similarity to the human enzyme (SEQ ID NO: l). Two highly homologous sequences derived from D. melanogaster have been identified and are designated as D.
  • the 1167 bp open reading frame of the D. melanogaster core 1 ⁇ 3-GalT # 1 gene is shown in SEQ ID NO : 18, and encodes the protein sequence of D. melanogaster core 1 ⁇ 3-GalT #1 (SEQ ID NO: 17).
  • the 1104 bp open reading frame of the D. melanogaster ⁇ 3-GalT #2 gene is shown in SEQ ID NO: 10, and encodes the protein sequence of D. melanogaster core 1 ⁇ 3-GalT #2 (SEQ ID NO:9).
  • melanogaster core 1 ⁇ 3-GalT #2 has 41% identity and 55% similarity to the human enzyme (SEQ ID NO:l).
  • a cDNA for the rat (R. norvegicus) core 1 ⁇ 3-GalT has also been identified herein and is shown in SEQ ID NO:4.
  • Bases 154-1245 of SEQ ID NO:4 correspond to the open reading frame, shown in SEQ ID NO: 13, which encodes the protein sequence of R. norvegicus core 1 ⁇ 3-GalT, which is shown in SEQ ID NO:3.
  • the rat core 1 ⁇ 3-GalT has 89% identity and 93% similarity to the human enzyme (SEQ ID NO: 1).
  • sequences having substantial sequence homology includes those nucleotide and amino acid sequences which have slight or inconsequential sequence variations from the sequences disclosed in the Sequence Listings, i.e. the homologous sequences function in substantially the same manner to produce substantially the same polypeptides as the actual sequences.
  • the variations may be attributable to local mutations or structural modifications.
  • Substantially homologous (identical) sequences further include sequences having at least 41% sequence homology (identity) with the ⁇ 3-GalT polynucleotide or polypeptide sequences shown herein or other percentages as defined elsewhere herein.
  • the present invention includes polynucleotides represented by SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 and SEQ ID NO: 18, and coding sequences thereof (SEQ ID NO: 12,
  • SEQ ID NO:5 SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO: 17, respectively.
  • Each polynucleotide comprises untranslated regions upstream and/or downstream of the coding sequence and a coding sequence (which by convention includes the stop codon).
  • a comparison of the ⁇ 3-GalTs identified herein revealed considerable homology in specific portions of the amino acid sequences.
  • SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO: 17 had homologous loci which had 100% identity with amino acid residues 120- 123, 167-173, 208-213, 254-259, 271-275, and 307-311 of SEQ ID NO: 1 (h- ⁇ 3-GalT).
  • the ⁇ 3-GalTs further had homologous loci having at least 60%, 67% and 63% identity with h ⁇ 3-GalT amino acid residues 97-126, 143-224, and
  • the ClustalW program has two alignment variables, the gap creation penalty and the gap extension penalty, which can be modified to alter the stringency of a nucleotide and/or amino acid alignment produced by the program.
  • Delay Divergent 40% The program used the BLOSUM series scoring matrix. Other parameter values used in the percent identity determination were default values previously established for the 6.5 version of the ClustalW program, (see Thompson, J.D. et al (1994) Nucleic Acids Res 22:4673).
  • polynucleotides which encode core 1 ⁇ 3-galactosyl transferases are contemplated by the present invention.
  • the present invention contemplates DNA sequences having SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 and SEQ ID NO: 18, and DNA sequences comprising bases 63-1154 of SEQ ID NO:2 (SEQ ID NO: 12), bases 154-1245 of SEQ ID NO:4 (SEQ ID NO: 13), bases 180-1271 of SEQ ID NO:6 (SEQ ID NO: 14), and bases 1-1170 of SEQ ID NO:8 (SEQ ID NO:15).
  • the invention further comprises portions of said sequences which encode soluble forms of ⁇ 3-GalTs.
  • the invention further contemplates DNA sequences which comprise portions of polynucleotides of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 10 and SEQ ID NO: 18 which encode soluble proteins having ⁇ 3-galactosyl transferase activity. That is, portions of the above polynucleotides which encode the N-terminal transmembrane region have been removed, and the remaining portions encode soluble proteins having ⁇ 3- galactosyl trasnferase activity.
  • the invention further contemplates polynucleotides which are at least about 50% homologous, 60% homologous, 70% homologous, 80% homologous or 90% homologous to the coding sequence SEQ ID NO: 12, where homology is defined as strict base identity, wherein said polynucleotides encode proteins having ⁇ 3-galactosyl transferase activity.
  • the present invention further contemplates nucleic acid sequences which differ in the codon sequence from the nucleic acids defined herein due to the degeneracy of the genetic code, which allows different nucleic acid sequences to code for the same protein as is further explained herein above and as is well known in the art.
  • the polynucleotides contemplated herein may be DNA or RNA.
  • the invention further comprises DNA or RNA nucleic acid sequences which are complementary to the sequences described above.
  • the present invention further comprises polypeptides which are encoded by the polynucleotide sequences described above.
  • the present invention contemplates polypeptides having ⁇ 3-galactosyl transferase activity including SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO: 17 and versions thereof which lack the transmembrane domain and which are therefore soluble.
  • the invention further contemplates polypeptides which are at least about 41% homologous, 50% homologous, 60% homologous, 70% homologous, 80% homologous, or 90% homologous to the polypeptides represented herein by, SEQ ID NO: 1 or SEQ ID NO: 3, wherein homology is defined as strict identity.
  • the present invention further contemplates polypeptides having loci in substantially homologous positions which have at least about 60% or greater identity with residues 97-126, about 67% or greater identity with residues 143-224, and about 63% or greater identity with residues 239-330 of SEQ ID NO :1 , and which have ⁇ 3-galactosyl transferase activity.
  • the present invention further contemplates polypeptides which differ in amino acid sequence from the polypeptides defined herein by substitution with functionally equivalent amino acids, resulting in what are known in the art as conservative substitutions, as discussed above herein.
  • isolated DNA sequences which hybridize to the DNAs set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:61 SEQ ID NO:8, SEQ ID NO: 10 or SEQ ID NO: 18 under stringent or relaxed conditions (as well known to persons of ordinary skill in the art), and which have ⁇ 3-galactosyl transferase activity.
  • melanogaster ⁇ 3-galactosyl transferases that catalyze galactosylation of an N- acetylgalactosamine linked to a serine or threonine on a protein, polypeptide or peptide have been cloned and expressed.

Abstract

On décrit des β3-galactosyle transférases de coeur (1) et des acides nucléiques codant les β3-galactosyle transférases de coeur (1). Les enzymes et les acides nucléiques codant lesdites enzymes ont été identifiés dans D. melanogaster et C.elegans chez l'homme, le rat et la souris. Les polypeptides présentent une gamme étendue d'homologies. Les polynucléotides peuvent être utilisés pour transformer ou transfecter des cellules hôtes afin de produire des formes sensiblement pures de l'enzyme ou pour servir dans un système d'expression permettant d'effectuer la glycosylation post-traductionnelle à liaison O de coeur (1) de protéines ou de peptides produits dans le système d'expression. Les enzymes peuvent être utilisées pour le galactosylate, via une liaison β3-, une N-acétylgalactosamine liée à une sérine, une thréonine ou un autre acide aminé à liaison sur des peptides ou des protéines nécessitant une glycosylation à liaison O.
PCT/US2000/033945 1999-12-15 2000-12-14 $g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes WO2001044478A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA02005953A MXPA02005953A (es) 1999-12-15 2000-12-14 Beta 3-galactosil transferasas de nucleo 1 y metodos de uso de las mismas.
AU27273/01A AU2727301A (en) 1999-12-15 2000-12-14 Core 1 beta3-galactosyl transferases and methods of use thereof
EP00990216A EP1240334A2 (fr) 1999-12-15 2000-12-14 $g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes
CA002396654A CA2396654A1 (fr) 1999-12-15 2000-12-14 .beta.3-galactosyle transferases de coeur 1 et procedes d'utilisation associes
JP2001545555A JP2003527103A (ja) 1999-12-15 2000-12-14 コア１β３−ガラクトシルトランスフェラーゼおよびその使用方法
HK03100430.5A HK1048140A1 (zh) 1999-12-15 2003-01-17 核心1β3-半乳糖基轉移酶及其方法和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46132199A 1999-12-15 1999-12-15
US09/461,321 1999-12-15
US09/464,035 US6492152B1 (en) 1999-06-15 1999-12-15 Core 1 β3-galactosyl transferases and methods of use thereof
US09/464,035 1999-12-15

Publications (3)

Publication Number Publication Date
WO2001044478A2 true WO2001044478A2 (fr) 2001-06-21
WO2001044478A3 WO2001044478A3 (fr) 2002-01-31
WO2001044478A9 WO2001044478A9 (fr) 2002-07-11

Family

ID=27039987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033945 WO2001044478A2 (fr) 1999-12-15 2000-12-14 $g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes

Country Status (7)

Country Link
EP (1) EP1240334A2 (fr)
JP (1) JP2003527103A (fr)
AU (1) AU2727301A (fr)
CA (1) CA2396654A1 (fr)
HK (1) HK1048140A1 (fr)
MX (1) MXPA02005953A (fr)
WO (1) WO2001044478A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147405A1 (fr) * 2006-04-05 2008-12-04 Oklahoma Medical Research Foundation Utilisation d'o-glycanes dans le traitement d'affections intestinales inflammatoires et de cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679716A1 (fr) * 1993-11-12 1995-11-02 Kenichi Matsubara Signature genique
WO1999051185A2 (fr) * 1998-04-03 1999-10-14 Incyte Pharmaceuticals, Inc. Galactosyltransferases humaines
WO1999065712A2 (fr) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptide, technique de synthese et utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679716A1 (fr) * 1993-11-12 1995-11-02 Kenichi Matsubara Signature genique
WO1999051185A2 (fr) * 1998-04-03 1999-10-14 Incyte Pharmaceuticals, Inc. Galactosyltransferases humaines
WO1999065712A2 (fr) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptide, technique de synthese et utilisation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADAMS M D ET AL: "The genome sequence of Drosophila melanogaster" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, 24 March 2000 (2000-03-24), pages 2185-2195, XP002144875 ISSN: 0036-8075 *
AMADO M ET AL: "A Family of human beta3-Galactosyltransferases (subtitle: characterization of four members of a udp-galactose:BETA-n-acetyl-glu cosamine/BETA-nacetyl-galactosamine BETA-1,3- galactosyltransferase family" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 21, 22 May 1998 (1998-05-22), pages 12770-12778, XP002109786 ISSN: 0021-9258 *
AMADO M ET AL: "IDENITFICATION AND CHARACTERIZATION OF LARGE GALACTOSYLTRANSFERASE GENE FAMILIES: GALACTOSYLTRANSFERASES FOR ALL FUNCTIONS" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1473, no. 1, 6 December 1999 (1999-12-06), pages 35-53, XP001015944 ISSN: 0006-3002 *
JU, T.-Z. ET AL: "Purification, cloning and expression of core 1 beta3-galactosyltransferase. " GLYCOBIOLOGY, vol. 9, no. 10, October 1999 (1999-10), page 86 XP001023067 *
LEPPANEN ANNE ET AL: "A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 35, 27 August 1999 (1999-08-27), pages 24838-24848, XP002176950 ISSN: 0021-9258 *
SHERWOOD A L ET AL: "STABLE EXPRESSION OF A CDNA ENCODING A HUMAN BETA1 -->3GALACTOSYLTRANSFERASE RESPONSIBLE FOR LACTO-SERIES TYPE 1 CORE CHAIN SYNTHESIS IN NON-EXPRESSING CLLS: VARIATION IN THE NATURE OF CELL SURFACE ANTIGENS EXPRESSED" JOURNAL OF CELLULAR BIOCHEMISTRY, LISS, NEW YORK, NY, US, vol. 50, no. 2, 1 October 1992 (1992-10-01), pages 165-177, XP000676088 ISSN: 0730-2312 *
WILSON R ET AL: "2.2 MB OF CONTIGUOUS NUCLEOTIDE SEQUENCE FROM CHROMOSOME III OF C. ELEGANS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 368, no. 6466, 3 March 1994 (1994-03-03), pages 32-38, XP002029739 ISSN: 0028-0836 *
ZENG STEFFEN ET AL: "Complete enzymic synthesis of the mucin-type sialyl Lewis x epitope, involved in the interaction between PSGL-1 and P-selectin." GLYCOCONJUGATE JOURNAL, vol. 16, no. 9, 1999, pages 487-497, XP001016300 ISSN: 0282-0080 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147405A1 (fr) * 2006-04-05 2008-12-04 Oklahoma Medical Research Foundation Utilisation d'o-glycanes dans le traitement d'affections intestinales inflammatoires et de cancers

Also Published As

Publication number Publication date
EP1240334A2 (fr) 2002-09-18
MXPA02005953A (es) 2003-01-28
AU2727301A (en) 2001-06-25
CA2396654A1 (fr) 2001-06-21
WO2001044478A3 (fr) 2002-01-31
JP2003527103A (ja) 2003-09-16
HK1048140A1 (zh) 2003-03-21
WO2001044478A9 (fr) 2002-07-11

Similar Documents

Publication Publication Date Title
KR102522263B1 (ko) polX 패밀리의 DNA 폴리머라제의 변형체
US7575885B2 (en) Tyrosylprotein sulfotransferases and methods of use thereof
US6492152B1 (en) Core 1 β3-galactosyl transferases and methods of use thereof
WO2016119756A1 (fr) Protéine mutante de glycosyltransférase et utilisations de cette dernière
JP2002504376A (ja) ヒト血小板ヘパラナーゼポリペプチド、それをコードするポリヌクレオチド分子、およびヘパラナーゼ活性を改変する化合物の同定方法
JPH1066585A (ja) ヒト軟骨糖蛋白質
US6071732A (en) Tyrosylprotein sulfotransferases, nucleic acids encoding tyrosylprotein sulfotransferases, and methods of use thereof
US6461835B1 (en) Fucosyltransferases, polynucleotides encoding fucosyltransferases, and transgenic mammal incorporating same
US20030235884A1 (en) Polynucleotides encoding core 1 beta3-galactosyl transferase and methods of use thereof
US6713283B2 (en) Tyrosylprotein sulfotransferases
EP1240334A2 (fr) $g(b)3-galactosyle transferases de coeur 1 et procedes d'utilisation associes
US20030059915A1 (en) Core 1 beta3-galactosyl transferases and methods of use thereof
EP1379639B1 (fr) Glucuronyle c5-epimerase de la souris, adn codant pour celle-ci et utilisation associee
JP2002085082A (ja) スーパーオキシドジスムターゼ−４
US6207414B1 (en) Tyrosylprotein sulfotransferases and methods of use thereof
JP3527250B2 (ja) Ｇｄｐ―フコースピロホスホリラーゼをコードする核酸
US7273754B2 (en) Core 1 β3-galactosyltransferase specific molecular chaperones, nucleic acids, and methods of use thereof
US6204016B1 (en) Tyrosylprotein sulfotransferases and methods of use thereof
JP5233347B2 (ja) 組換ヤナギマツタケ・ガレクチン
US6207432B1 (en) Tyrosylprotein sulfotransferases and methods of use thereof
US20040086995A1 (en) Beta1, 4-N-Acetylgalactosaminyltransferases, nucleic acids and methods of use thereof
US6605455B1 (en) Tyrosylprotein sulfotransferases and methods of use thereof
WO2000014250A1 (fr) Polypeptides de tyrosylproteine sulfotransferase et polynucleotides
EP1124970A1 (fr) Procede de purification de phospholipase a2 associee a une lipoproteine de faible densite (ldl-pla 2?) au moyen d'une chromatographie par affinite avec un metal immobilise
WO1999038980A9 (fr) Polypeptides et polynucleotides de tyrosylproteine-sulfotransferases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005953

Country of ref document: MX

Ref document number: 2000990216

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 545555

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2396654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 008181942

Country of ref document: CN

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000990216

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000990216

Country of ref document: EP